Host: |
Rabbit |
Applications: |
WB |
Reactivity: |
Human/Mouse |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-ADRA1B (500-600) is suitable for use in Western Blot research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.02% Sodium Azide, 50% Glycerol, pH7.3. |
Purification: |
Affinity purification |
Dilution Range: |
WB 1:500-1:2000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
ADRA1B |
Gene ID: |
147 |
Uniprot ID: |
ADA1B_HUMAN |
Immunogen Region: |
500-600 |
Immunogen: |
A synthetic peptide corresponding to a sequence within amino acids 500-600 of human ADRA1B (P35368). |
Immunogen Sequence: |
ADVANGQPGFKSNMPLAPGQ F |
Function | This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes. |
Protein Name | Alpha-1b Adrenergic ReceptorAlpha-1b AdrenoreceptorAlpha-1b Adrenoceptor |
Database Links | Reactome: R-HSA-390696Reactome: R-HSA-416476Reactome: R-HSA-416482 |
Cellular Localisation | Nucleus MembraneMulti-Pass Membrane ProteinCell MembraneCytoplasmMembraneCaveolaLocation At The Nuclear Membrane Facilitates Heterooligomerization And Regulates Erk-Mediated Signaling In Cardiac MyocytesSignaling In Cardiac MyocytesColocalizes With GnaqPlcb1 As Well As Lap2 At The Nuclear Membrane Of Cardiac Myocytes |
Alternative Antibody Names | Anti-Alpha-1b Adrenergic Receptor antibodyAnti-Alpha-1b Adrenoreceptor antibodyAnti-Alpha-1b Adrenoceptor antibodyAnti-ADRA1B antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance